Biogen Inc

More Details of Biogen Inc Company

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Company Info

Ticker SymbolBIIB

Company nameBiogen Inc

IPO dateSep 17, 1991

Founded at1997

CEOMr. Christopher A. (Chris) Viehbacher

Number of employees7605

Security typeOrdinary Share

Fiscal year-endSep 17

Address225 Binney Street

CityCAMBRIDGE

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02142

Phone17814642000

Websitehttps://www.biogen.com/

Ticker SymbolBIIB

IPO dateSep 17, 1991

Founded at1997

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Jesus B. Mantas

Independent Director

8.42K

+39.19%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+76.33%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.43K

-41.22%

Ms. Susan Langer

Independent Director

3.79K

+166.90%

Name

Name/Position

Position

Shareholding

Change

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Revenue Breakdown

Currency: USDUpdated: 10 hours ago

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Spinal Muscular Atrophy-SPINRAZA

563.30M

23.17%

MS product revenues-TYSABRI

381.50M

15.69%

MS product revenues-Fumarate

344.90M

14.19%

MS product revenues-Interferon

226.30M

9.31%

Biosimilar product revenues-BENEPALI

111.30M

4.58%

Other

803.70M

33.06%

By RegionUSD

Name

Revenue

Proportion

Rest of World

972.70M

40.01%

United States

786.80M

32.37%

United states-Revenues from anti-CD20 therapeutic

378.20M

15.56%

Rest of World-Other revenues

293.30M

12.06%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Spinal Muscular Atrophy-SPINRAZA

563.30M

23.17%

MS product revenues-TYSABRI

381.50M

15.69%

MS product revenues-Fumarate

344.90M

14.19%

MS product revenues-Interferon

226.30M

9.31%

Biosimilar product revenues-BENEPALI

111.30M

4.58%

Other

803.70M

33.06%

Shareholding Stats

Updated: Sat, May 17

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

11.57%

PRIMECAP Management Company

10.88%

BlackRock Institutional Trust Company, N.A.

5.94%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.19%

Other

63.37%

Shareholders

Proportion

The Vanguard Group, Inc.

11.57%

PRIMECAP Management Company

10.88%

BlackRock Institutional Trust Company, N.A.

5.94%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.19%

Other

63.37%

Shareholder Types

Shareholders

Proportion

Investment Advisor

40.61%

Investment Advisor/Hedge Fund

37.38%

Hedge Fund

6.51%

Research Firm

2.41%

Pension Fund

2.34%

Bank and Trust

1.79%

Sovereign Wealth Fund

1.66%

Individual Investor

0.17%

Family Office

0.08%

Other

7.06%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

2052

136.48M

93.14%

-10.45M

2025Q1

2149

136.82M

93.38%

-11.44M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

2023Q1

2280

132.71M

91.84%

-5.88M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

16.96M

11.57%

+279.20K

+1.67%

Mar 31, 2025

PRIMECAP Management Company

15.94M

10.88%

-102.95K

-0.64%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

8.70M

5.94%

+106.24K

+1.24%

Mar 31, 2025

State Street Global Advisors (US)

7.40M

5.05%

-1.34K

-0.02%

Mar 31, 2025

Wellington Management Company, LLP

4.67M

3.19%

-258.29K

-5.24%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.85M

2.63%

+151.39K

+4.10%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

3.04M

2.07%

+51.65K

+1.73%

May 31, 2025

T. Rowe Price Investment Management, Inc.

2.66M

1.82%

-439.50K

-14.18%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

2.33M

1.59%

+246.45K

+11.86%

Dec 31, 2024

Invesco Capital Management LLC

2.01M

1.37%

+124.81K

+6.62%

Mar 31, 2025

Related ETFs

Updated: Wed, Jul 2

Name

Proportion

Invesco Biotechnology & Genome ETF

4.81%

iShares Neuroscience and Healthcare ETF

4.03%

First Trust NASDAQ Pharmaceuticals ETF

3.74%

First Trust NYSE Arca Biotechnology Index Fund

3.54%

VanEck Biotech ETF

3.53%

Tema Neuroscience and Mental Health ETF

3.18%

Invesco Pharmaceuticals ETF

2.7%

SPDR S&P Biotech ETF

2.46%

First Trust Health Care Alphadex Fund

2.2%

ProShares Ultra Nasdaq Biotechnology

2.13%

Invesco Biotechnology & Genome ETF

Proportion4.81%

iShares Neuroscience and Healthcare ETF

Proportion4.03%

First Trust NASDAQ Pharmaceuticals ETF

Proportion3.74%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.54%

VanEck Biotech ETF

Proportion3.53%

Tema Neuroscience and Mental Health ETF

Proportion3.18%

Invesco Pharmaceuticals ETF

Proportion2.7%

SPDR S&P Biotech ETF

Proportion2.46%

First Trust Health Care Alphadex Fund

Proportion2.2%

ProShares Ultra Nasdaq Biotechnology

Proportion2.13%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

133.190USD

Biogen Inc

133.190

Overview

Company